The Collaborative Ocular Melanoma Study: An Overview

Abstract

Background

The Collaborative Ocular Melanoma Study (COMS) is a 3-arm study that includes two multicenter randomized clinical trials designed to compare the effectiveness of brachytherapy to enucleation for treatment of medium-size choroidal melanomas, and the effectiveness of enucleation with and without preoperative external-beam radiotherapy for large choroidal melanomas. The third arm is an observational study of small choroidal melanomas. Patient accrual ran from 1987 to 1998.

Methods

A review of COMS published reports was conducted.

Results

There is no difference in 5-year all-cause mortality for large- and medium-size choroidal melanomas with COMS-designated treatments. Preoperative radiation for large choroidal melanomas does not improve survival. The accuracy of the clinical diagnosis of choroidal melanoma is excellent.

Conclusions

Data from the trials are still being collected and analyzed, but primary outcomes will unlikely change significantly in the future. Similar rates of mortality after treatment with enucleation and brachytherapy shift the emphasis of selection of therapy to secondary outcomes such as preservation of vision. The findings highlight the need to better understand the biological mechanisms and timing of hematogenous dissemination to achieve an appreciable impact on choroidal melanoma survival.

References

Egan

K.M.

, Seddon

J.M.

, Glynn

R.J.

Epidemiologic aspects of uveal melanoma. Surv Ophthalmol. 1988; 32: 239–251.

Jemal

, Thomas

, Murray

Cancer statistics, 2002. CA Cancer J Clin. 2002; 52: 23–47.

Inskip

P.D.

, Devesa

S.S.

, Fraumeni

J.F.

Jr . Trends in the incidence of ocular melanoma in the United States, 1974-1998. Cancer Causes Control. 2003; 14: 251–257.

Margo

C.E.

, McLean

I.W.

Malignant melanoma of the choroid and ciliary body in black patients. Arch Ophthalmol. 1984; 102: 77–79.

Margo

C.E.

, Mulla

Incidence of surgically treated uveal melanoma by race and ethnicity. Ophthalmology. 1998; 105: 1087–1090.

Zimmerman

L.E.

, McLean

I.W.

, Foster

W.D.

Does enucleation of the eye containing a malignant melanoma prevent or accelerate the dissemination of tumour cells?

Br J Ophthalmol. 1978; 62: 420–425.

Markowitz

J.A.

, Hawkins

B.S.

, Diener-West

A review of mortality from choroidal melanoma. I. Quality of published reports, 1966 through 1988. Arch Ophthalmol. 1992; 110: 239–244.

Diener-West

, Hawkins

B.S.

, Markowitz

J.A.

A review of mortality from choroidal melanoma. II. A meta-analysis of 5-year mortality rates following enucleation, 1966 through 1988. Arch Ophthalmol. 1992; 110: 245–250.

Kujala

, Makitie

, Kivela

Very long-term prognosis of patients with malignant uveal melanoma. Invest Ophthalmol Vis Sci. 2003; 44: 4651–4659.

10.

Moy

C.S.

, Albert

D.M.

, Diener-West

Cause-specific mortality coding: methods in the collaborative ocular melanoma study COMS report No. 14. Control Clinic Trial. 2001; 22: 248–262.

11.

Augsburger

J.J.

, Gamel

J.W.

, Sardi

V.F.

Enucleation vs cobalt plaque radiotherapy for malignant melanomas of the choroid and ciliary body. Arch Ophthalmol. 1986; 104: 655–661.

12.

Packer

, Rotman

Radiotherapy of choroidal melanoma with iodine-125. Ophthalmology. 1980; 87: 582–590.

13.

Lommatzsch

P.K.

Results after beta-irradiation (106Ru/106Rh) of choroidal melanomas: 20 years’ experience. Br J Ophthalmol. 1986; 70: 844–851.

14.

Adams

K.S.

, Abramson

D.H.

, Ellsworth

R.M.

Cobalt plaque versus enucleation for uveal melanoma: comparison of survival rates. Br J Ophthalmol. 1988; 72: 494–497.

15.

Guthoff

, Frischmuth

, Jensen

O.A.

Choroid melanoma: a retrospective randomized comparative study of ruthenium irradiation vs enucleation. Klin Monatsbl Augenheilkd. 1992; 200: 257–261.

16.

Gass

J.D.

Comparison of prognosis after enucleation vs cobalt 60 irradiation of melanomas. Arch Ophthalmol. 1985; 103: 916–923.

17.

Cruess

A.F.

, Augsburger

J.J.

, Shields

J.A.

Regression of posterior uveal melanomas following cobalt-60 plaque radiotherapy. Ophthalmology. 1984; 91: 1716–1719.

18.

Servodidio

, Abramson

The Collaborative Ocular Melanoma Study. In: Kertes

P.J.

, Conway

M.D.

, eds. Clinical Trials in Ophthalmology: A Summary and Practice Guide. Baltimore, Md: Williams & Wilkins; 1998.

19.

Collaborative Ocular Melanoma Study Group. Assessment of metastatic disease status at death in 435 patients with large choroidal melanoma in the Collaborative Ocular Melanoma Study (COMS): COMS report No. 15. Arch Ophthalmol. 2001; 119: 670–676.

20.

The Collaborative Ocular Melanoma Study (COMS) randomized trial of pre-enucleation radiation of large choroidal melanoma, II: initial mortality findings. COMS report No. 10. Am J Ophthalmol. 1998; 125: 779–796.

21.

The Collaborative Ocular Melanoma Study (COMS) randomized trial of pre-enucleation radiation of large choroidal melanoma III: local complication and observation following enucleation COMS report No. 11. Am J Ophthalmol. 1998; 126: 362–371.

22.

Diener-West

, Earle

J.D.

, Fine

S.L.

The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma, III: Initial mortality findings. COMS report No. 18. Arch Ophthalmol. 2001; 119: 969–982.

23.

The Collaborative Ocular Melanoma Study Group. Accuracy of diagnosis of choroidal melanomas in the Collaborative Ocular Melanoma Study. COMS report No. 1. Arch Ophthalmol. 1990; 108: 1268–1273.

24.

Jampol

L.M.

, Moy

C.S.

, Murray

T.G.

The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: IV. Local treatment failure and enucleation in the first 5 years after brachytherapy. COMS report No. 19. Ophthalmology. 2002; 109: 2197–2206.

25.

Melia

B.M.

, Abramson

D.H.

, Albert

D.M.

Collaborative ocular melanoma study (COMS) randomized trial of 1-125 brachytherapy for medium choroidal melanoma. I. Visual acuity after 3 years COMS report No. 16. Ophthalmology. 2001; 108: 348–366.

26.

Straatsma

B.R.

, Diener-West

, Caldwell

Mortality after deferral of treatment or no treatment for choroidal melanoma. Am J Ophthalmol. 2003; 136: 47–54.

27.

Mortality in patients with small choroidal melanoma. COMS report No. 4. The Collaborative Ocular Melanoma Study Group. Arch Ophthalmol. 1997; 115: 886–893.

28.

Margo

C.E.

The accuracy of diagnosis of posterior uveal melanoma. Arch Ophthalmol. 1997; 115: 432–434.

29.

Friedman

L.M.

, Furberg

C.D.

, DeMets

D.L.

, eds. Fundamentals of Clinical Trials. 3rd ed. New York: Springer; 1998.

30.

Augsburger

J.J.

, Gamel

J.W.

, Lauritzen

Cobalt-60 plaque radiotherapy vs enucleation for posterior uveal melanoma. Am J Ophthalmol. 1990; 109: 585–592.

31.

Edwards

M.G.

, Schachat

A.P.

Impact of enucleation for choroidal melanoma on the performance of vision-dependent activities. Arch Ophthalmol. 1991; 109: 519–521.

32.

Melia

, Moy

C.S.

, Reynolds

S.M.

Development and validation of disease-specific measures for choroidal melanoma. COMS-QOLS report No. 2. Arch Ophthalmol. 2003; 121: 1010–1020.

33.

Puusaari

, Heikkonen

, Summanen

Iodine brachytherapy as an alternative to enucleation for large uveal melanomas. Ophthalmology. 2003; 110: 2223–2234.

34.

Beck

R.W.

Clinical research in pediatric ophthalmology: the Pediatric Eye Disease Investigator Group. Curr Opin Ophthalmol. 2002; 13: 337–340.

35.

Karlsson

U.L.

, Augsburger

J.J.

, Shields

J.A.

Recurrence of posterior uveal melanoma after 60Co episcleral plaque therapy. Ophthalmology. 1989; 96: 382–388.

36.

Egan

K.M.

, Ryan

L.M.

, Gragoudas

E.S.

Survival implications of enucleation after definitive radiotherapy for choroidal melanoma: an example of regression on time-dependent covariates. Arch Ophthalmol. 1998; 116: 366–370.

37.

Robertson

D.M.

Changing concepts in the management of choroidal melanoma. Am J Ophthalmol. 2003; 136: 161–170.